AIAISci
English

科技社区情报流

科学迷社区

像看英超和懂球帝一样看 AI 与 Biotech：最新论文、科研成果、人物、实验室、证据来源、商业化信号和关系图谱集中在一个信息流里。

已审核信号
601
证据来源
721
追踪领域
12
全球总榜蛋白质与药物设计93 条匹配动态
clinical updateBiotecheditor reviewed
Rising signal62

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

原始来源文本: Clinical/translation signal: Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

AISci 已验证editor reviewed / 1 证据来源
机构
Protein and Drug Design
1 证据来源
Source 1: ClinicalTrials.gov
打开论文工作台打开图谱语境
clinical updateBiotecheditor reviewed
Rising signal62

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

原始来源文本: Clinical/translation signal: Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

AISci 已验证editor reviewed / 1 证据来源
机构
Protein and Drug Design
1 证据来源
Source 1: ClinicalTrials.gov
打开论文工作台打开图谱语境
clinical updateBiotecheditor reviewed
Rising signal62

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

原始来源文本: Clinical/translation signal: Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

AISci 已验证editor reviewed / 1 证据来源
机构
Protein and Drug Design
1 证据来源
Source 1: ClinicalTrials.gov
打开论文工作台打开图谱语境
clinical updateBiotecheditor reviewed
Rising signal62

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

原始来源文本: Clinical/translation signal: Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

AISci 已验证editor reviewed / 1 证据来源
机构
Protein and Drug Design
1 证据来源
Source 1: ClinicalTrials.gov
打开论文工作台打开图谱语境
clinical updateBiotecheditor reviewed
Rising signal60

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

原始来源文本: Clinical/translation signal: Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

AISci 已验证editor reviewed / 1 证据来源
机构
Protein and Drug Design
1 证据来源
Source 1: ClinicalTrials.gov
打开论文工作台打开图谱语境
clinical updateBiotecheditor reviewed
Rising signal60

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

原始来源文本: Clinical/translation signal: Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

AISci 已验证editor reviewed / 1 证据来源
机构
Protein and Drug Design
1 证据来源
Source 1: ClinicalTrials.gov
打开论文工作台打开图谱语境
clinical updateBiotecheditor reviewed
Rising signal59

pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

原始来源文本: Clinical/translation signal: pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

AISci 已验证editor reviewed / 1 证据来源
机构
Protein and Drug Design
1 证据来源
Source 1: ClinicalTrials.gov
打开论文工作台打开图谱语境